Profile data is unavailable for this security.
About the company
Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
- Revenue in USD (TTM)628.56m
- Net income in USD141.82m
- Incorporated1998
- Employees352.00
- LocationCorcept Therapeutics Inc101 REDWOOD SHORES PARKWAYREDWOOD CITY 94065United StatesUSA
- Phone+1 (650) 688-8803
- Fax+1 (650) 327-3218
- Websitehttps://www.corcept.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PTC Therapeutics, Inc. | 900.66m | -453.20m | 3.33bn | 988.00 | -- | -- | -- | 3.70 | -5.94 | -5.94 | 11.79 | -13.70 | 0.5807 | 1.97 | 4.93 | 911,603.30 | -29.22 | -26.71 | -45.34 | -33.46 | 92.20 | 93.94 | -50.32 | -83.80 | 2.04 | -0.7925 | 1.79 | -- | 34.20 | 28.78 | -12.09 | -- | 32.00 | -- |
| Apellis Pharmaceuticals Inc | 715.22m | -250.10m | 3.83bn | 702.00 | -- | 16.43 | -- | 5.35 | -2.04 | -2.04 | 5.81 | 1.94 | 0.8316 | 0.8814 | 3.19 | 1,018,828.00 | -29.08 | -73.88 | -37.24 | -90.03 | 86.47 | -- | -34.97 | -326.49 | 3.73 | -9.20 | 0.656 | -- | 425.83 | -- | 18.94 | -- | -- | -- |
| Perrigo Company PLC | 4.39bn | -146.90m | 3.83bn | 9.14k | -- | 0.849 | 20.75 | 0.8719 | -1.07 | -1.17 | 32.07 | 33.45 | 0.40 | 2.46 | 5.58 | 480,525.20 | -1.34 | -0.1148 | -1.51 | -0.1315 | 36.07 | 35.28 | -3.34 | -0.2985 | 1.77 | 1.26 | 0.51 | -- | 4.58 | -0.3238 | 96.64 | -- | -5.95 | 7.52 |
| Organon & Co | 6.41bn | 1.30bn | 3.94bn | 10.00k | 3.21 | 8.45 | 2.52 | 0.614 | 5.04 | 5.04 | 24.81 | 1.91 | 0.5394 | 2.08 | 3.85 | 640,900.00 | 10.95 | 16.53 | 14.08 | 20.97 | 58.26 | 65.12 | 20.30 | 26.79 | 1.21 | 2.73 | 0.9467 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.91 | -- |
| Prestige Consumer Healthcare Inc | 1.11bn | 205.95m | 4.19bn | 570.00 | 20.62 | 2.42 | 17.65 | 3.77 | 4.11 | 4.11 | 22.14 | 35.03 | 0.334 | 3.13 | 6.90 | 1,948,525.00 | 6.19 | 3.69 | 6.42 | 3.84 | 55.21 | 56.79 | 18.54 | 12.19 | 2.10 | 5.68 | 0.3779 | 0.00 | -0.21 | 2.89 | 354.34 | -- | -1.84 | -- |
| BridgeBio Pharma Inc | 217.77m | -438.86m | 4.43bn | 550.00 | -- | -- | -- | 20.33 | -2.41 | -2.41 | 1.19 | -6.51 | 0.33 | -- | -- | 395,936.40 | -67.62 | -72.44 | -85.06 | -89.72 | 98.90 | 94.41 | -204.94 | -1,225.66 | -- | -9.40 | 3.43 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
| Axsome Therapeutics Inc | 338.46m | -310.96m | 4.78bn | 545.00 | -- | 50.84 | -- | 14.13 | -6.54 | -6.54 | 7.11 | 1.92 | 0.5824 | 2.49 | 3.34 | 621,022.00 | -53.51 | -64.55 | -73.04 | -82.23 | 91.09 | -- | -91.87 | -227.05 | 2.37 | -60.51 | 0.6648 | -- | 440.80 | -- | -27.84 | -- | 77.86 | -- |
| ADMA Biologics Inc | 382.81m | 68.13m | 5.01bn | 624.00 | 77.70 | 21.89 | 65.58 | 13.08 | 0.2763 | 0.2763 | 1.61 | 0.981 | 1.04 | 1.17 | 9.40 | 613,475.40 | 18.42 | -24.80 | 20.87 | -28.00 | 48.93 | 17.40 | 17.80 | -51.31 | 3.26 | 7.58 | 0.3041 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
| Avidity Biosciences Inc | 10.12m | -280.49m | 5.16bn | 253.00 | -- | 3.57 | -- | 510.05 | -2.90 | -2.90 | 0.1028 | 12.64 | 0.0091 | -- | -- | 39,988.14 | -25.34 | -31.61 | -27.05 | -34.45 | -- | -- | -2,772.45 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
| Corcept Therapeutics Incorporated | 628.56m | 141.82m | 6.03bn | 352.00 | 46.49 | 9.65 | 42.17 | 9.59 | 1.27 | 1.27 | 5.64 | 6.12 | 0.9121 | 1.26 | 13.32 | 1,785,668.00 | 20.58 | 21.17 | 25.10 | 23.85 | 98.44 | 98.52 | 22.56 | 27.23 | 3.64 | -- | 0.00 | 0.00 | 20.04 | 13.93 | 4.66 | 7.08 | -14.15 | -- |
| Halozyme Therapeutics, Inc. | 947.36m | 392.47m | 6.23bn | 373.00 | 15.81 | 13.43 | 13.15 | 6.58 | 3.02 | 3.02 | 7.30 | 3.56 | 0.4724 | 1.30 | 3.77 | 2,539,826.00 | 19.57 | 18.22 | 20.73 | 21.97 | 82.09 | 79.05 | 41.43 | 39.36 | 9.15 | -- | 0.7687 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
| Elanco Animal Health Inc | 4.45bn | 205.00m | 6.60bn | 9.30k | 32.77 | 1.01 | 7.56 | 1.48 | 0.4087 | 0.4087 | 8.99 | 13.20 | 0.3224 | 1.21 | 5.09 | 478,924.70 | 1.48 | -3.27 | 1.64 | -3.65 | 54.69 | 54.28 | 4.60 | -11.53 | 1.31 | 0.9883 | 0.4005 | -- | 0.136 | 7.57 | -1,478.21 | -- | 2.74 | -- |
| Jazz Pharmaceuticals PLC | 3.99bn | 463.16m | 7.66bn | 2.80k | 17.51 | 1.80 | 6.86 | 1.92 | 7.10 | 7.10 | 60.27 | 69.01 | 0.3404 | 0.7371 | 5.91 | 1,425,969.00 | 3.97 | 1.48 | 4.46 | 1.62 | 89.37 | 88.79 | 11.65 | 4.26 | 3.74 | 2.82 | 0.5944 | 0.00 | 4.78 | 15.19 | 285.14 | -1.49 | -20.04 | -- |
Data as of Nov 25 2024. Currency figures normalised to Corcept Therapeutics Inc's reporting currency: US Dollar USD
51.20%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2024 | 13.74m | 13.15% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 9.76m | 9.34% |
| Ingalls & Snyder LLCas of 30 Sep 2024 | 8.27m | 7.91% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 6.51m | 6.23% |
| Parallel Advisors LLCas of 30 Sep 2024 | 3.81m | 3.65% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 3.52m | 3.37% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 2.43m | 2.32% |
| Geode Capital Management LLCas of 30 Sep 2024 | 2.38m | 2.28% |
| Arrowstreet Capital LPas of 30 Sep 2024 | 1.58m | 1.51% |
| Boston Trust Walden, Inc.as of 30 Sep 2024 | 1.51m | 1.45% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
